Please enter your license information:
Efficacy Profile
A1C at 102 weeks graph full text
- A1C graph showing the demonstrated reduction in A1C from baseline over 102 weeks for Trajenta®.
- X-axis shows the treatment duration in weeks with the number of patients at that timepoint in brackets, as follows: 0 (1,531), 6 (1,490), 12 (1,463), 18 (1,440), 24 (1,429), 30 (1,400), 42 (1,302), 54 (1,183), 66 (1,090), 78 (1,007), 90 (948) and 102 (903).
- On the Y-axis is the percent change from baseline A1C from 0 to -1.00. Week 0 to 24 reflects data for a double-blind, placebo-controlled trial. Week 24 to 102 reflects data for an open-label extension. Line shows demonstrated reductions in A1C from baseline through to Week 102.
- A 0.8% decrease in A1C was shown from baseline at Week 102.
Are you thinking Trajenta®?
![Healthcare professional and patient Healthcare professional and patient](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/login-banner-updated.png)
Are you a Canadian
View coverage details for Trajenta® and Jentadueto®
![Map of Canada Map of Canada](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/check-coverage-icon.png)